Agenus Names BAP Pharma as Exclusive Global Partner for BOT+BAL Access Programs

LEXINGTON, Mass. & MARLOW, England--(BUSINESS WIRE)---- $AGEN #AAC--Agenus Inc. (Nasdaq: AGEN), a leader in immuno-oncology innovation, and BAP Pharma, a global medicines access and clinical trial supply company, today announced the exclusive appointment of BAP Pharma as Agenus' global partner for botensilimab (BOT) plus balstilimab (BAL) authorized global access programs. The partnership supports compliant, patient-focused access to BOT+BAL through authorized pathways where permitted by local regulations. Ef.